Asheville Eye Associates - Retina Division — Asheville, North Carolina

Asheville Eye Associates - Retina Division is a clinical research site located in Asheville, North Carolina, United States 28803.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Asheville Eye Associates - Retina Division has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization.

Sponsors: EyeBiotech Ltd., Annexon, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Asheville

Browse all research sites in North Carolina · View every site in Asheville

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Asheville Eye Associates - Retina Division?

Asheville Eye Associates - Retina Division has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Asheville Eye Associates - Retina Division conducted?

Asheville Eye Associates - Retina Division has 2 clinical trials on record, with 2 currently active. Their work covers Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization.

Is Asheville Eye Associates - Retina Division accredited by Crixeo Clinical Trials?

Asheville Eye Associates - Retina Division has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Asheville Eye Associates - Retina Division?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.